RSV immunisation programme for young children would cost €19m, new figures show

Hiqa said its assessment would help to inform future Government policy on immunisation for RSA.

It would cost up to €19m to vaccinate Ireland’s infant population against respiratory syncytial virus (RSV), a disease which saw 2,500 children admitted to hospital in 2022.

An assessment by the Health Information and Quality Authority (Hiqa) looked at the options around providing immunisations to both the young and older populations of Ireland given they are at particular risk from RSV.